134 related articles for article (PubMed ID: 38233095)
1. Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases.
Revés J; Torres J
J Crohns Colitis; 2024 Jan; ():. PubMed ID: 38233095
[No Abstract] [Full Text] [Related]
2. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Ibing S; Cho JH; Böttinger EP; Ungaro RC
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
[TBL] [Abstract][Full Text] [Related]
3. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2023 Dec; ():. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
5. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37921344
[TBL] [Abstract][Full Text] [Related]
6. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
7. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.
Reinglas J; Gonczi L; Kurt Z; Bessissow T; Lakatos PL
World J Gastroenterol; 2018 Aug; 24(32):3567-3582. PubMed ID: 30166855
[TBL] [Abstract][Full Text] [Related]
8. 10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study.
Koo HM; Jun YK; Choi Y; Shin CM; Park YS; Kim N; Lee DH; Shin YK; Yoon H
Therap Adv Gastroenterol; 2023; 16():17562848231201728. PubMed ID: 37786473
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Kikawa Y; Kotake T; Tsuyuki S; Kang Y; Takahara S; Fujimoto Y; Yamashiro H; Yoshibayashi H; Takada M; Yasuoka R; Nakatsukasa K; Yamagami K; Suwa H; Okuno T; Nakayama I; Kato T; Ogura N; Moriguchi Y; Ishiguro H; Kagimura T; Taguchi T; Sugie T; Toi M
Breast Cancer; 2022 Sep; 29(5):796-807. PubMed ID: 35460066
[TBL] [Abstract][Full Text] [Related]
10. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
Shapina MV; Nanaeva BA
Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
12. The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
Crouwel F; Bayoumy AB; Mulder CJJ; Peters JHC; Boekema PJ; Derijks LJJ; de Boer SY; van de Meeberg PC; Ahmad I; Buiter HJC; de Boer NK
Inflamm Bowel Dis; 2023 Sep; ():. PubMed ID: 37658804
[TBL] [Abstract][Full Text] [Related]
13. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.
Thomas PWA; den Broeder N; Derikx M; Kievit W; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F
Inflamm Bowel Dis; 2022 Dec; 28(12):1813-1820. PubMed ID: 35134917
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience.
Macaluso FS; Maida M; Grova M; Crispino F; Teresi G; Orlando A; Orlando A
Therap Adv Gastroenterol; 2021; 14():17562848211010668. PubMed ID: 33995582
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
Bouhnik Y; Atreya R; Casey D; Górecki M; Baik D; Yoon SW; Kwon TS; Jang M
Inflamm Bowel Dis; 2023 Jun; 29(6):898-913. PubMed ID: 35942647
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.
Huynh L; Hass S; Peyrin-Biroulet L; Duh MS; Sipsma H; Cheng M; Lax A; Nag A
Crohns Colitis 360; 2022 Jan; 4(1):otac001. PubMed ID: 36777550
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: Promise and perils.
Singh S
Best Pract Res Clin Gastroenterol; 2019; 38-39():101614. PubMed ID: 31327401
[TBL] [Abstract][Full Text] [Related]
19. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
20. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
